RecruitingEarly Alzheimer's Disease

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Eligible age

50–85 yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Sponsor: Merck Sharp & Dohme LLC

You may qualify if…

✓ The main inclusion criteria include but are not limited to the following:
✓ Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
✓ Has a designated study partner who can fulfill the requirements of this study
✓ If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening

You may not qualify if…

✕ The main exclusion criteria include but are not limited to the following:
✕ Has a known history of stroke or cerebrovascular disease
✕ Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
✕ Has structural brain disease
✕ Has a history of seizures or epilepsy within 5 years before screening
✕ Has any other major central nervous system trauma, or infections that affect brain function
✕ Has major medical illness or unstable medical condition within 3 months before screening
✕ Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality